Erythroid differentiation-associated gene (EDAG) is a hematopoietic tissue-specific gene that is highly expressed in the earliest CD34 þ lin À bone marrow (BM) cells and involved in the proliferation and differentiation of hematopoietic cells. To investigate the role of EDAG in hematopoiesis, we established an EDAG transgenic mouse model driven by human CD11a promoter. The transgenic mice showed increased mortality with severe organ infiltration by neutrophils, and the homeostasis of hematopoiesis was broken. The myelopoiesis was enhanced with expansion of myeloid cells in BM, increased peripheral granulocytes and extramedullary myelopoiesis in spleen. In contrast to myeloid cells, the lymphoid commitment was severely impaired with the B lymphopoiesis blocked at the transition from pro/pre-B I to pre-B II stage in BM and T thymocytes development blocked at the most immature stage (DN I). Moreover, we showed that EDAG was a transcriptional regulator which had transactivation activity and regulated the expression of several key transcription factors such as PU.1 and Pax5 in transgenic hematopoietic stem cells. These data suggested that EDAG was a key transcriptional regulator in maintaining the homeostasis of hematopoietic lineage commitment.
Introduction
Human Erythroid differentiation-associated gene (EDAG), (also known hemgn in mouse, 1 and RP59 in rat 2 ) encodes a 484-amino-acid protein that is expressed predominantly in hematopoietic tissues such as bone marrow (BM) and fetal liver. EDAG/ hemgn contains a nuclear localization sequence (NLS) and a coiled-coiled domain. The human and mouse proteins show 43% identity, although the identity between the NLS and coiledcoiled domains are higher. 1 Studies on the developmental expression pattern of mouse hemgn reveal its hematopoietic ontogeny. hemgn transcripts are specifically detected in blood islands, primitive blood cells and fetal liver during mouse embryogenesis. They are downregulated in the process of blood cell differentiation during embryogenesis and then remain in the BM and spleen of adult mice. Among adult hematopoietic lineages, hemgn is predominantly expressed in erythroid and megakaryocytic precursor cells, hematopoietic stem cells (HSCs) (lin (lo) Sca þ kit þ ) and early progenitors. 1 Study of the regulation mechanism of its expression suggests that hemgn is a direct target of transcription factor GATA-1. 3 Moreover, hemgn is also expressed in testis in a variant splice form using an alternative promoter, suggesting a complex regulation mechanism of its expression. 4 Just like hemgn, EDAG is primarily expressed in immature precursors, such as CD34 þ progenitor cells, and is downregulated during maturation of blood cells. 1 No EDAG transcript is detected in peripheral blood mononuclear cells (PBMCs) or other non-hematopoietic tissues. 5 In addition to normal adult hematopoietic cells, EDAG expression is very high in leukemia cell lines such as erythroleukemia cell lines (K562, HEL and Mo7e), 6 and megakaryoblast leukemia cell lines (DAMI, MEG-01). 7 Moreover, high levels of EDAG mRNA were also detected in PBMCs of patients with leukemia. 5 Studies in hematopoietic cell lines also suggest that EDAG is generally downregulated during terminal differentiation and its forced expression leads to promotion of proliferation, enhanced survival and inhibition of differentiation. 5 Recently, association of overexpression of EDAG and poor prognosis in de novo acute myeloid leukemia (AML) has been reported, suggesting that EDAG plays a modulator role in AML. 8 From these results, we reason that EDAG may play a key role in hematopoiesis and its ectopic expression may be related to a leukemia-like phenotype.
To understand the role of EDAG in hematopoiesis, we generated EDAG transgenic mice that selectively expressed EDAG in hematopoietic tissue under the control of human CD11a promoter. EDAG overexpression resulted in a hematopoietic defect that the myelopoiesis was enhanced with a progressive myeloid hyperplasia, whereas the lymphopoiesis was inhibited with decreased B compartments in BM and blocked T-cell development in thymus. In addition, we identified EDAG as a novel transcriptional regulator that had transactivation activity and maybe regulate the expression of several key hematopoietic transcription factors in HSCs.
Methods and materials

Transgenic mice
The EDAG transgenic construct was established by cloning the full-length human EDAG cDNA into the BamHI site of the pfGH vector under the control of CD11a promoter. To generate the CD11a-EDAG transgenic mice, a 5.1-kilobase (kb) HindIII/NsiI fragment containing the CD11a-EDAG transgenic cassette cDNA was isolated from an agarose gel, purified using the DNApurification kit (Promega Corp., Madison, WI, USA), extracted with phenol-chloroform and ethanol-precipitated. DNA fragment was microinjected into fertilized eggs of KunMing mice to generate transgenic founders. Founders were screened by reverse transcription-PCR (RT-PCR) using primers complementary to the EDAG and GH-coding sequences and Southern blot analysis. All mice were bred and maintained at the animal facility under specific pathogen-free conditions. All experiments using mice received approval from the Beijing Institute of Radiation Medicine Administrative Panel for the Animal Care.
Southern blot analysis
Tail DNA samples were prepared as previously described 7 and digested with BglII to generate a 1.4-kb fragment. The digests were separated on a 0.8% agarose gel and transferred to a positively charged nylon membrane (Biotrans plus, ICN, Costa Mesa, CA, USA). EDAG cDNA was labeled with 32 P-dCTP and used as probes to hybridize with the genomic tail DNA samples to test for the presence of the transgenic constructs.
RT-PCR analysis
Total RNA was isolated using Trizol reagent (Gibco Invitrogen, Carlsbad, CA, USA) and 1 mg total RNA was reverse-transcribed using reverse the transcription kit (Promega) and amplified with PCR kits (Perkin Elmer, Boston, MA, USA) according to the manufacturer's instructions. Each gene was analyzed using specific primer pairs (sequence available upon request). The PCR products were electrophoresed on 1% agarose gels and photographed. For quantification of transgene expression in different animal lines, BM cells were harvested and total RNA was extracted. Then a standard real-time RT-PCR was performed with SYBR PrimeScript RT-PCR kit (Takara Biotechnology Co., Ltd., Dalian, China).
Western blot analysis
Twenty micrograms of protein from each sample was loaded onto the gel. After separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the proteins were transferred to nitrocellulose membranes and probed with EDAG antibodies at a concentration of 1:2000. Chemiluminescent detection was conducted using a supersignal substrate (Pierce, Rockford, IL, USA) according to the manufacturer's specifications.
Analysis of PB cells and histopathology
PB cells, hemoglobin and platelet counts were measured by using an automated hemacytometer (Table 1) . Differential counts of PB and BM were performed microscopically on Wright-Giemsa-stained smears. A minimum of 100 cells of PB and 200-400 cells for BM were examined, and the percentage of blast cells was counted. Sections (4 mm) from various hematopoietic organs, including lung, liver and kidney, were stained with hematoxylin and eosin and examined.
Flow cytometry and cell sorting BM cells were harvested from femurs and tibia. Spleens were collected and single-cell suspensions were prepared by passing the tissues through a 70 mm nylon mesh. PB were obtained from tail veins. All cells were treated with ACK (ammonium chloride lysing solution) (8.3 g/l ammonium chloride, 1 g/l potassium bicarbonate, 0.4 g/l ethylenediamine tetraacetic acid) to lyse red blood cells. Liver leukocytes were prepared as previously described. 9 Cell suspensions were washed in phosphatebuffered saline (PBS) and resuspended at 10 7 cells/ml in PBS þ 2% fetal calf serum before immunostaining. Cells were labeled with antibodies for 30 min at 41C, analyzed with a FACSCaliber flow cytometer and quantitated with CELLQUEST software (both from BD Biosciences, San Jose, CA, USA). The following antibodies were used: anti-c-kit-PE-Cy5, anti-CD44-FITC, anti-CD11b-FITC, anti-B220-FITC, anti-IgM-PE, anti-CD25-PE, anti-Gr-1-PE, anti-IgM-PE, anti-CD3-PE, anti-CD4-FITC, anti-CD8-FITC, anti-TER119-FITC and antiSca-1-PE (BD Pharmingen, San Diego, CA, USA). HSCs (Lin 11 were sorted by FACS based on isotype control.
Colony assays
We carried out in vitro clonogenic assays in Methocult M3534 (StemCell Technologies, Vancouver, BC, Canada) containing recombinant mouse stem cell factor (rmSCF), rmIL-3 and rhIL-6 to support growth of colony-forming units-granulocyte/macro- Table 1 PB counts of transgenic mice and control littermates 2-6 months 6-24 months 
GAL4-based transcriptional activation assay in yeast
For transcriptional activation assay in yeast, a recombinant vector encoding GAL4 DNA-binding domain (DBD) and EDAG fusion protein (pGBKT7-EDAG) were constructed by subcloning the full-length of EDAG cDNA into pGBKT7 (Clontech Palo Alto, CA, USA). The yeast host strain, AH109 was transformed with pGBKT7-EDAG to investigate whether pGBKT7-EDAG autonomously activates the lacZ reporter genes. pCL plasmid encoding the wild-type GAL4 protein was used as a positive control. b-Galactosidase activity was analyzed by the colony-lift filter method, and the appearance of a blue color on the colonies within 2 h after the addition of substrate was considered a positive reaction. Positive reaction was routinely reconfirmed by the liquid assay.
GAL4-based transcriptional activation assay in mammalian cells
For mammalian transactivation activity, the EDAG cDNA was cloned into pM vector (Clontech) to generate GAL4 DBD-EDAG fusion protein. The fused plasmid pM-EDAG was then cotransfected with GAL4-responsive luciferase reporter plasmid pFRLuc (Stratagene, La Jolla, CA, USA) in a ratio of 1:8 into human embryonic kidney 293 cells by using pM3VP16 as a positive control and pM vector as a negative control. Cell extracts were prepared 24 h after transfection to measure the luciferase activity with a luciferase assay kit (Promega) in a chemiluminescence analyzer (FB12 luminometer; Berthold Detection Systems, Montreal Biotech Inc., CA, USA). Luciferase activities were expressed as fold induction relative to the values obtained from control cells. All transfections were normalized according to Renilla-luciferase activity, which was encoded by phRL-TK plasmid (Promega) and used as an internal control for transfection.
Isolation of the human PU.1 promoter
The sequence 5 0 of exon 1 of the human PU.1 gene was amplified and cloned from human genomic DNA (PB of a normal donor) by PCR based on the published sequence, 12 with primer A (5 0 -GGGGTACCCTCAAAAGAAGCAGGC-3 0 ) and primer B (5 0 -GAAGATCTCCTGCCGCTGGGAGATAGTCCC-3 0 ). The synthesized fragment was 517-bp long, extending from À487 to þ 30 with the transcription start site. The PCR fragment was then cloned into the vector pGL3-basic (PU.1-pGL3).
Results
Transgenic EDAG is predominantly expressed in hematopoietic tissues
Human CD11a (leukocyte function-associated antigen, LFA-1) is the a-subunit of the integrin heterodimers CD11a/CD18 and is expressed on early hematopoietic progenitors, and only lost from the erythroid lineage during differentiation. 13 Its promoter has been used previously to drive expression of gene to hematopoietic cells. 14, 15 To investigate the role of EDAG in hematopoietic development, we engineered EDAG overexpression in hematopoietic cells of mice under the control of human CD11a promoter. Positive founder mice were identified by Southern blot analysis of tail DNA and RT-PCR of PB cells. Of 78 pups, three positive founder mice were identified (Figures 1a  and b) . Real-time quantitative PCR revealed that each transgenic line contained an equal number of transgenes (data not shown). Real-time RT-PCR on total BM of the three lines and wild-type littermates was also performed. This assay revealed that the EDAG mRNA of the three lines was about five times the expression level of endogenous hemgn (Table 2) . Breeding strains were established from these three mice, and the transgenic progeny displayed human EDAG in all of their nucleated blood cells. Western blot analysis suggested that in strain 7, the transgenic EDAG was predominantly expressed in hematopoietic tissues such as BM, spleen and thymus, but not in the testis, brain, heart, lung, muscle and kidney (Figure 1c) . The same expression profile of transgenic EDAG was also obtained from strains 2 and 8 (data not shown). Table 1 , the transgenic mice at 2-6 months of age appeared in good health and the different PB numbers were indistinguishable from littermate control mice. However, in transgenic mice at 6-24 months of age, the leukocyte numbers in the PB were twofold higher than that in control mice. Differential blood counts indicated elevated number of mature neutrophilic granulocytes, but comparable numbers of lymphocytes, eosinophilic granulocytes, erythrocytes and monocytes. The platelets were slightly reduced in transgenic mice. Since the transgenic EDAG mRNA levels were similar in the three strains, all the progeny from the three founders gave very similar blood profiles and phenotypes and no dose-dependent effect was observed either. To rule out possible integration effects, the subsequent data have been combined from these three strains. Flow cytometric assay was further performed to assess the myeloid cell compartment of 12-month-old mice BM for the surface expression of CD11b. As shown in Figure 2a , the myeloid cells (CD11b þ ) were significantly increased. It is known that granulocytic cells of adult mouse express CD11b and high amounts of Gr-1 on the cell surface, whereas monocytic cells express CD11b and little or no Gr-1. 16 We then assessed CD11b and Gr-1 expression and found that the increase of CD11b þ cells was mainly due to the increase of granulocytes (CD11b þ Gr-1 þ ) from 30.6 to 62.6%, whereas the number of CD11b þ Gr-1 À monocytic cells did not alter dramatically (5.5% in transgenic BM versus 3.0% in control) (Figure 2b) . In morphologic analysis, the transgenic BM was tightly packed by cells, with an obvious dominance of granulocytic cells (Figure 2c ). Flow cytometric assay on the splenocytes also indicated that the relative and absolute numbers of myeloid cells were increased in the spleen of transgenic mice (Figure 2d ). These results suggested that EDAG transgenic mice developed a progressive myeloid hyperplasia, with overproduction of mature neutrophilic granulocytes.
To examine whether the increased granulocytes was due to an increased ability of CMPs to generate CFU-GM, CMPs were isolated from transgenic and control BM and seeded in the equal number in Methocult M3534 containing rmSCF, mIL-3 and rhIL-6, supporting the growth of CFU-GM. As shown in Figure 2e , a comparable number of colonies were formed from both control and transgenic mice. In contrast, when splenocytes were cultured in Methocult M3534, the number of CFU-GM was elevated in cultures from transgenic splenocytes, showing a twofold increase (Figure 2f) . Furthermore, when transgenic splenocytes were cultured in Methocult M3234 supplemented with granulocyte/macrophage colony-stimulating factor (GM-CSF) supporting growth of myeloid progenitors, the number of formed colonies was also increased about 2.5-fold (Figure 2f ). These results indicated that although the differentiation rate of CMP to granulocytes was not affected, overexpression of EDAG promoted extramedullary myelopoiesis.
Suppression of lymphopoiesis in EDAG transgenic mice
In contrast to the enhanced myelopoiesis, a threefold reduction in the percentage of B lymphoid cells (B220 þ ) was observed in transgenic BM (Figure 3a) . B220
þ cells are divided into three distinct entities: B220 þ c-kit þ represents the pro/pre-B I cells; B220 þ CD25 þ represents the pre-B II cells; B220 þ IgM þ represents the immature/mature B cells. 17 To define the stage of a possible block in B-cell development, we assessed the expression of CD25, c-kit and IgM on the surface of B220 þ cells. As shown in Figure 3a , a 95% decrease in pre-B II (B220 þ CD25 þ ) cells and an B50% decrease in immature/ mature B-lineage subpopulations (B220 þ IgM þ ) were observed in transgenic BM. However, the percentage of pro/pre-B I subpopulation was comparable to the control (0.82% in transgenic BM versus 0.79% in control). Since B-cell development is a consecutive process progressing from pro/pre-B I through pre-B II to immature/mature B cells, the more severe reduction of pre-B II and immature/mature B subpopulations indicated that overexpression of EDAG blocked B-cell development at the transition from pro/pre-B I to pre-B II stage.
To further characterize whether the defect in B-cell lymphopoiesis was due to a decreased ability of CLPs to generate CFUpre-B, BM CLPs were isolated for CFU assays. BM CLPs from transgenic and control mice were seeded in equal number in Methocult M3630 containing rmIL-7 to support growth of pre-B colonies; after 8 days, colonies were counted. As shown in Figure 3b , a threefold decrease in the ability of transgenic CLPs to generate CFU-pre-Bs compared with wild-type CLPs was observed. In addition, the few detected EDAG-expressing pre-B colonies were also smaller in size than littermate control mice (data not shown). This finding suggested that while enhancing myelopoiesis, EDAG suppressed B lymphopoiesis in BM by decreasing the ability of CLPs to differentiate to B lymphoid lineage.
We also examined the effect of EDAG on T thymocytes development. The cellularity of the transgenic thymus decreased by about threefold compared with control mice (Figure 3c ). Flow cytometric analysis revealed dramatically reduced number of CD4/CD8 double positive (DP) cells in transgenic mice (Figure 3d ) (3.5 versus 88.24% in control). This reduced DP representation correlated with arrested development within the most immature thymocytes of CD4/CD8 double negative (DN) subpopulation. Based on the differential expression of CD44 and CD25, DN cells development can be divided into four stages, progressing from CD44 þ CD25 À (DN I) progenitors through the CD44 À CD25 þ (DN II) and CD44 À CD25 þ (DN III) stages to CD44 À CD25 À (DN IV) cells. 18 We next analyzed the CD44/CD25 expression profile of DN thymocytes to further characterize the stage of developmental arrest. As shown in Figure 3e , the percentage of DN I cells in transgenic thymus was increased significantly compared with the control mice, suggesting that ectopic EDAG expression arrested early T-cell development at the DN I stage.
Increased mortality of transgenic mice with severe organ infiltration by neutrophils As described above, transgenic mice at 2-6 months of age appeared in good health and were indistinguishable from littermate control mice. However, from 6 months of age transgenic mice became moribund, and 17 of 50 transgenic mice died during the period of 6-24 months of age. KaplanMeier analysis demonstrated that EDAG mice displayed increased mortality (Figure 4a ). The moribund mice developed severe splenomegaly (Figure 4b ) and the total cellularity of the spleen was increased threefold, as reflected in a higher spleen weight: 0.487 mg (n ¼ 8) versus 0.096 mg (n ¼ 6), Po0.01. The transgenic liver exhibited a disrupted morphology (Figure 4c ), characterized by a large pale region on the surface. Histological examination of transgenic mice revealed prevalent infiltration of the liver, lung and kidney by neutrophils (Figure 4d ). Flow cytometric analysis of transgenic liver leukocytes confirmed the significantly increased number of granulocytes (CD11b þ Gr-1 þ ) (Figure 4e ).
EDAG alters transcription factors in HSCs and functions as a transcriptional regulator
Accumulated evidence has revealed that transcription factors play critical roles in the regulation of hematopoietic development. 19 So several key hematopoietic transcription factors were analyzed by RT-PCR in primary BM HSCs (Lin À Sca-1 þ c-kit þ ). As shown in Figure 5a , transcription factors such as PU.1, MEF, HoxA9, c-Myb and C/EBPa were significantly upregulated, whereas Pax5 was downregulated. We did not detect significant differences in expression of RUNX1, Tal-1 or GATA-1 between transgenic mice and control.
Since EDAG plays a key role in the hematopoiesis just as described above and is located in nucleus, 6 we investigated if EDAG is a transcription factor. We first analyzed the EDAGmediated transcriptional activation using a GAL4-based transactivation activity assay system in yeast. A plasmid that fused EDAG cDNA with the Gal4 DBD was constructed (pGBKT7-EDAG) and transformed into stain AH109 yeast. Transcriptional activity was assessed using a chromosomally integrated b-galactosidase reporter gene (lacZ). The results indicated that Gal4 DBD-EDAG fusion protein alone could effectively activate expression of the LacZ reporter gene (Figure 5b) . Furthermore, the result was confirmed with a Gal4-based transactivation assay in mammalian cells. The plasmid pM-EDAG encoding a Gal4 DBD-EDAG fusion protein was cotransfected with the pFR-Luc reporter plasmid, which contains five consensus GAL4-binding sites upstream of luciferase gene into 293 cells. As shown in Figure 5c , pM-EDAG alone activated the expression of the luciferase reporter gene about eightfold over the pM vector. These results indicated that EDAG was a transcriptional regulator with transactivation activity.
To understand the role of EDAG in the alteration of hematopoietic transcription factors, we analyzed the effect of EDAG on the promoter of transcription factor PU.1. A 517-bp fragment of PU.1 promoter was cloned into pGL3-basic reporter vector (PU.1-pGL3) and was cotransfected with pcDNA3.1 or pcDNA3.1-EDAG vector into 293 cells in which endogenous PU.1 is absent. Based on the luciferase activity assay, EDAG increased the transcriptional activity of PU.1 promoter by twofold, which indicated that EDAG might be a transactivator of PU.1 (Figure 5d ).
Discussion
The EDAG gene was originally isolated from fetal liver, and previous studies suggest that EDAG is critical for proliferation and differentiation of hematopoietic cells. 5 While EDAG mRNA is expressed in HSCs and early progenitors, it is not expressed in mature hematopoietic cells. Moreover, EDAG has been reported to be downregulated in the maturation of blood cell. Thus, EDAG is thought to play an important role in hematopoiesis. In this study, we provided direct evidence that overexpression of EDAG disrupted hematopoietic homeostasis by causing imbalance between myelopoiesis and lymphopoiesis. Increased EDAG levels led to the expansion of myeloid cells in BM, resulting in a significant increase of mature granulocytes in PB and extramedullary myelopoiesis in spleen. In contrast to myeloid cells, the lymphoid lineage was severely impaired, with the B lymphopoiesis blocked at the transition from pro/pre-B I to pre-B II stage in BM and T thymocytes development blocked at the most immature stage (DN I). Analysis of CMPs and CLPs showed that although the ability of CMPs to generate CFU-GM was not affected, overexpression of EDAG decreased the production of B lymphoid lineage by CLPs. These data suggest that EDAG acts as a key regulator in primitive hematopoietic cells and its downregulation during maturation of blood cells is necessary for maintaining the homeostasis of hematopoietic lineage commitment. Although EDAG is also expressed in erythroid and megakaryocytic cells, we did not investigate significant alterations of the two lineages in transgenic mice except that the platelets were slightly reduced, which may be due to the use of CD11a promoter.
The lineage commitment decision of HSCs is a highly regulated process, which involves fundamental changes in gene expression, resulting in each cell type expressing a characteristic complement of genes necessary for its function. Lineage switching seems to occur between cells whose genetic profile differs only in a few key genes. From a number of previous studies, a variety of transcription factors whose expressions are confined to hematopoietic cells and exhibit a 'spatio-temporal' specific pattern have emerged as key components of the regulatory processes. For example, the transcription factor SCL is thought to exert important functions in progenitors and in specific lineages of the hematopoietic compartment. SCL expression follows a differentiation-dependant gradient: it is expressed in HSCs and the most primitive progenitors but becomes downregulated as differentiation preceeds. 20 Overexpression of SCL in transgenic mice results in a severe block of B-cell differentiation at the early pro-B stage, with decrease in the expression level of Pax-5. 21 The Hox transcription factor family members HoxA9, HoxB3 and HoxA10 also have been characterized as key regulators in hematopoietic differentiation. These genes are specifically expressed in primitive HSCs (CD34 þ ) and downregulated with progression to BM CD34 À cells, and undetectable in mature circulating monocytes and granulocytes. 22 Alteration of their expression level in mice results in impaired hematopoiesis. HoxA9 transgenic mice show enhanced myelopoiesis and inhibition of lymphopoiesis 23 just as EDAG does. HoxB3 transgenic mice develop a myeloproliferative disorder. 24 Overexpression of HoxA10 perturbs both myeloid and lymphoid differentiation and leads to AML. 25 Thus, the genes being transcribed at high levels in HSCs always play essential roles in the hematopoietic development and their downregulation in the differentiation process is an important regulation pattern for normal hematopoiesis. Here, we first identify EDAG as a hematopoietic transcription regulator that plays an essential role in the development of HSCs and propose that maintenance of its low concentration in the later differentiation stage is required for myeloid versus lymphoid commitment decision.
It is widely assumed that lineage-specific gene expression programs are established and maintained by both positive and negative interactions between transcription factors that are expressed in different compartments of the hematopoietic system. 26 The appropriate regulation of transcription factor networks is pivotal for maintaining proper tissue homeostasis within the hematopoietic compartment. Our present study showed that the transcription factors such as PU.1, MEF, HoxA9, c-Myb and C/EBPa were significantly upregulated in transgenic mice. These upregulated genes have been proved to play key roles in HSCs and myelopoiesis. High level of PU.1 is required for the development of myeloid lineages 27 and overexpression of PU.1 in multipotent progenitor cell line FDCP-mix results in the priming of myeloid differentiation. 28 C/ EBPa is considered to be a myeloid gene and deletion of C/EBPa in mice results in lack of granulocytic cells. 29 c-Myb is identified as a regulator of the commitment of CMP and progenitors restricted to the myeloid lineage.
30 HoxA9 transgenic mice demonstrate inhibition of lymphopoiesis and induced myelopoiesis. 23 Interestingly, we found that a B-lineage-related gene Pax5 was downregulated in transgenic mice. Previous studies suggest that Pax5 is absolutely required for B lymphocyte commitment and loss of Pax5 results in a B-cell developmental block. 31 Accordingly, the B lymphopoiesis inhibition in EDAG transgenic mice may be due to downregulation of Pax5. However, whether or not the downregulation of Pax5 is a direct consequence of EDAG overexpression requires further confirmation, because the networks in the transcription factors are complex. Studies on PU.1 function provide a good example. Two clues have been found to account for how the active function of PU.1 could lead to mutually exclusive outcomes: lymphoid versus myeloid cells. First, the distinct effects of PU.1 on lineage commitment are dosage-related, with a higher concentration favoring HSCs commitment to myeloid cells. 28 Second, the PU.1 activity on its target gene could be negatively regulated by the lymphoid cell transcription factor Pax5. 32 So the imbalance of the hematopoiesis in EDAG transgenic mice seems to be a combined consequence of alterations of transcription factors such as upregulation of the myeloid related genes and repression of the genes related to lymphoid development.
Based on the nucleus localization of EDAG, we investigated whether EDAG is a transcription factor. Using a yeast and mammalian two-hybrid system, we found that EDAG had transactivation activity, suggesting that EDAG is a transcriptional regulator. Many transcriptional regulators reported previously were identified as transactivator or repressor simultaneously in a pathway-or tissue-dependent manner. SCL can either activate or repress transcription, depending on its integration within multifactorial complexes containing other essential hematopoietic or ubiquitously expressed regulators. 20 PU.1 activates the transcription of M-CSFR, 33 while repressing the transcription of GATA-1 34 in different cell models. Here, we also showed that EDAG expression caused upregulation of PU.1 and downregulation of Pax5 in HSCs, suggesting that EDAG may positively or negatively regulate transcription of specific target genes. However, whether the effect of EDAG on these genes is direct needs further determination, since we have no evidence now that EDAG can bind DNA directly.
Our previous study also suggests that overexpression of EDAG in pro-B Ba/F3 cells prolongs survival and resists the apoptosis. 5 Moreover, overexpression of EDAG in NIH3T3 cells causes malignant transformation. 35 Furthermore, EDAG is mapped to chromosome 9q22, which is a breakpoint in several hematological neoplasms and contains a cluster of genes important for leukemogenesis. These results, together with its ectopic expression in PB cells of patients with leukemia, raise the possibility that the EDAG may act as a potential oncogene and contribute to a leukemic phenotype. However, in the present transgenic mice model, EDAG is not sufficient to induce leukemia, but leads to a myeloproliferative disorder with myeloid hyperplasia, splenomegaly, extramedullary hematopoiesis and infiltration of neutrophils in non-hematopoietic tissues, resembling human chronic myeloid leukemia. Similar observations have been made with other oncogenes such as AML1-ETO, K-ras and SCL etc. In AML1-ETO transgenic mice, additional mutations such as another translocation of TEL/PDGFbR are required for leukemia to develop. 36 Oncogenic K-ras expression in myeloid progenitor cells has been shown to result in myeloproliferative disease but not AML. 37 SCL overexpression in thymus only exhibits weak oncogenicity and it efficiently collaborates with other oncogenes such as v-ABL, casein kinase II and N-Ras to induce aggressive T-cell tumors in vivo. 20 Leukemia phenotype requires at least two cooperating mutations: one that promotes proliferation and enhanced survival and one associated with impaired differentiation and an immortalization phenotype. Based on the results that EDAG-overexpressing Ba/F3 cells show improved viability but do not lose the cytokine dependence of growth, we conclude that EDAG contributes to the positive growth phenotype of myeloid cells, but not to the point of overt transformation in a mouse model. Additional 'hits' are required for leukemia to develop.
The results presented in this study suggest that EDAG is an important regulator of hematopoietic lineage commitment, playing a positive role in myelopoiesis, but negatively regulating lymphocytes development. However, further resolution of its regulation mechanism and identification of its target genes remain an important challenge.
